Paola Guglielmelli
Università degli Studi di Firenze
H-index: 78
Europe-Italy
Top articles of Paola Guglielmelli
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia | Haematologica | Francesco Mannelli Matteo Piccini Sara Bencini Giacomo Gianfaldoni Benedetta Peruzzi | 2024/1/1 |
CALR mutation burden in essential thrombocythemia and disease outcome | Blood Journal | Paola Guglielmelli Natasha Szuber Naseema Gangat Giulio Capecchi Chiara Maccari | 2024/1/22 |
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience | Blood Cancer Journal | Giuseppe G Loscocco Francesca Gesullo Giulio Capecchi Alessandro Atanasio Chiara Maccari | 2024/1/18 |
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study | Blood Cancer Journal | Arianna Ghirardi Alessandra Carobbio Paola Guglielmelli Alessandro Rambaldi Valerio De Stefano | 2024/4/22 |
Inherited polygenic effects on common hematological traits influence clonal selection on JAK2V617F and the development of myeloproliferative neoplasms | Nature Genetics | Jing Guo Klaudia Walter Pedro M Quiros Muxin Gu E Joanna Baxter | 2024/1/17 |
Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion | Blood Advances | Caterina Tretti Parenzan Anna Dal Molin Giorgia Longo Enrico Gaffo Alessia Buratin | 2024/3/12 |
A safety evaluation of ruxolitinib for the treatment of polycythemia vera | Valentina Boldrini Alessandro M Vannucchi Paola Guglielmelli | 2024/1/2 | |
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options | Annals of Hematology | Jean-Jacques Kiladjian Francisca Ferrer Marin Haifa Kathrin Al-Ali Alberto Alvarez-Larrán Eloise Beggiato | 2024/3/4 |
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus … | American Journal of Hematology | Giuseppe G Loscocco Giada Rotunno Francesco Mannelli Giacomo Coltro Francesca Gesullo | 2024/1 |
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes | Annals of Hematology | Tiziano Barbui Alessandra Carobbio Valerio De Stefano Alberto Alvarez-Larran Arianna Ghirardi | 2024/2 |
Benefit of early ruxolitinib initiation regardless of fibrosis grade in patients with primary myelofibrosis: a post hoc analysis of the single-arm phase 3b JUMP study | Cancers | Francesca Palandri Haifa Kathrin Al-Ali Paola Guglielmelli Mike W Zuurman Rajendra Sarkar | 2023/5/22 |
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis | Blood cancer journal | Paola Guglielmelli Chiara Maccari Benedetta Sordi Manjola Balliu Alessandro Atanasio | 2023/1/30 |
Phase 1/2 study of the activin receptor-like Kinase-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) As monotherapy or with ruxolitinib in patients with anemia due to … | Blood | Sanjay Mohan Stephen Oh Jean-Jacques Kiladjian Masahiro Takeuchi Jason Gotlib | 2023/11/28 |
Incidence of blast phase in myelofibrosis according to anemia severity | EJHaem | Barbara Mora Margherita Maffioli Elisa Rumi Paola Guglielmelli Marianna Caramella | 2023/8 |
Clinical and Prognostic Validation of the Reticulin, Collagen, Osteosclerosis (RCO) Score for Primary Myelofibrosis (PMF) | Blood | Giacomo Coltro Raffaella Santi Giuseppe Gaetano Loscocco Alessandro Atanasio Paolo Cicogna | 2023/11/28 |
AML-251 APL-Like Subset Within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating With Early-Onset Vascular Complications | Clinical Lymphoma Myeloma and Leukemia | Gaia Ciolli Francesca Crupi Matteo Piccini Sara Bencini Giacomo Gianfaldoni | 2023/9/1 |
Interpretable artificial intelligence (AI) differentiates prefibrotic primary myelofibrosis (prePMF) from essential thrombocythemia (ET): a multi-center study of a new clinical … | Blood | Andrew Srisuwananukorn Giuseppe Gaetano Loscocco Andrew T Kuykendall James M Dolezal Raffaella Santi | 2023/11/28 |
P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA | HemaSphere | Francesco Mannelli Matteo Piccini Sara Bencini Giacomo Gianfaldoni Benedetta Peruzzi | 2023/8/1 |
Diagnostic and therapeutic challenges in mast cell sarcoma | American Journal of Hematology | Francesco Mannelli Francesca Gesullo Carmela Mannarelli Fiorenza Vanderwert Stefano Lazzi | 2023 |
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model | Leukemia | Elisa Bianchi Sebastiano Rontauroli Lara Tavernari Margherita Mirabile Francesca Pedrazzi | 2023/5 |
